Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% in Bacterial Conjunctivitis
2017-002730-23Phase 3
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in bacterial conjunctivitis (BC) comparing Moxifloxacin AF Ophthalmic Solution 0.5% with Moxifloxacin AF Vehicle (2 arms). Primary endpoint: Clinical cure rate at Day 7.
02
Drugs
moxifloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on 2017-002730-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002730-23.